Introduction
The addition of a single β-linked N-acetylglucosamine moiety (O-GlcNAc; GlcNAcylation) to the hydroxyl groups of serine and/or threonine residues of target proteins is an inducible, reversible, and dynamic post-translational modification (PTM). Since its discovery in the early 1980s (44, 97) , O-GlcNAc has been found to have an abundance and protein distribution similar to phosphorylation, but thus far only about 600 GlcNAcylated proteins have been identified. Unlike traditional glycosylation, the O-GlcNAc modification is nearly exclusively located on cytoplasmic and nuclear proteins, and is not elongated into more complex glycan structures, such as those found on extracellular or luminal domains of membrane or secreted glycoproteins. O-GlcNAc is involved in a wide range of biological processes, ranging from cell cycle progression and transcription to signal transduction and metabolism (38, 93) . Emerging evidence suggests that elevated O-GlcNAcylation of proteins contributes to glucose toxicity and is strongly associated with hyperglycemia-induced insulin resistance, two major hallmarks of type II diabetes (see recent review (19) ). This review will provide a critical evaluation of three broad areas and experimental approaches used to support O-GlcNAc's putative roles in the pathogenesis of diabetes: 1) regulation of hexosamine biosynthetic pathway (HBP) flux, 2) regulation of O-GlcNAc cycling enzymes, and 3) O-GlcNAc site-specific regulation of protein function. Existing data highlights the need for a significant increase in research efforts that focus on defining O-GlcNAc's sitespecific regulation of metabolically relevant protein functions.
The Hexosamine Biosynthetic Pathway (HBP) and Insulin Resistance
Since the 1950's, there have been more than 1200 papers published linking hexosamine metabolism to diabetes. Over a decade ago, in vitro studies in rat adipocytes provided direct evidence supporting a link between flux through the HBP and the development of insulin 5 reversible in a dose-dependent manner in its ability to induce the insulin resistant phenotype (41, 74) . Sustained exposure to high glucose or glucosamine (both of which cause elevated UDP-GlcNAc levels) results in impaired insulin stimulated GLUT4 translocation and subsequent reduced insulin-stimulated glucose uptake in muscle cells, without affecting insulin receptor or GLUT4 protein expression levels (10, 41) . One potential problem with some of these earlier studies, is the possible depletion of ATP induced by large amounts of exogenous glucosamine (47) . However, more recent papers, which carefully controlled for ATP levels, still demonstrated that glucosamine is a potent inducer of insulin resistance (41, 88). Collectively, these studies suggest that a strong association exists between elevated intracellular UDP-GlcNAc levels and the occurrence of insulin resistance in vitro and in vivo.
However, a direct causal relationship between elevated UDP-GlcNAc levels and the development of insulin resistance still remains to be established and fully understood. As studies have shown that while high glucose and glucosamine treatments both lead to increases in UDP-GlcNAc and O-GlcNAc levels, they also can lead to oxidative and endoplasmic reticulum stress (67, 111, 116) . Both of which have been shown to cause chronic inflammation and insulin resistance (30) . This combined with the idea that PUGNAc and/or overexpression of OGT may increase O-GlcNAc to a level typically not achievable by high glucose suggests that caution should be used when drawing conclusions regarding functional roles of O-GlcNAc using these methods. These limitations also suggest that to completely understand O-GlcNAc and its functional roles, site-specific studies are required, and currently these types of studies are severely lacking. Furthermore, earlier studies in other systems demonstrate that UDP-GlcNAc is a potent feedback inhibitor of GFAT (62) , and therefore the nucleotide sugar could also provide an important negative feedback mechanism to regulate HBP flux. As a consequence, our knowledge regarding regulation of HBP can be considered limited as it remains unclear as to how up to milli-molar 6 concentrations of UDP-GlcNAc accumulate inside the cell. The presence of this possible feedback regulatory mechanism, as well as the other side effects of high glucose and glucosamine treatment, suggests that other mechanisms are likely involved in the establishment of insulin resistance, in addition to elevated HBP flux.
Regulation of O-GlcNAc Cycling Enzymes and Insulin Resistance
As stated above, excess flux through the HBP results in elevated UDP-GlcNAc levels and is strongly associated with insulin resistance ( Figure 1A ). In turn, O-GlcNAc transferase (OGT) catalytic activity is highly sensitive to UDP-GlcNAc concentrations (64) . Thus the global extent of GlcNAcylation is highly sensitive to flux through the HBP (11, 75, 83, 89, 119) , suggesting that nutrient flux through the HBP may also regulate O-GlcNAc cycling on proteins ( Figure 1B ). Since O-GlcNAc is abundant on signaling proteins, including those in the insulin signaling pathway, and has a complex interplay with phosphorylation, one likely mechanism for HBP-dependent insulin resistance is increased GlcNAcylation, which might antagonize phosphorylation dependent insulin signaling (11, 103) .
Two enzymes regulate the cycling of O-GlcNAc, O-GlcNAc transferase (OGT: uridine diphospho-N-acetylglucosmine: polypeptide β-N-acetyl-glucosaminyltransferase; (33, 35) and O-GlcNAcase (OGA: β-N-acetylglucosaminidase; (20, 26) ). Using UDP-GlcNAc as a donor substrate, OGT catalyzes the transfer of a single N-acetylglucosamine monosaccharide (GlcNAc) to the hydroxyl groups of serine and/or threonine residues of target proteins; while OGA catalyzes the removal of O-GlcNAc from proteins. The mechanism by which these two enzymes can dynamically regulate O-GlcNAc cycling in response to certain stimuli is currently not well understood. Understanding how OGT and OGA are regulated will provide insight into the regulatory mechanisms by which OGT and OGA and subsequent GlcNAcylation are involved in insulin signaling and insulin resistance. The following section 7 briefly discusses how perturbation of these two enzymes expression and/or activities is linked to insulin resistance.
Regulation of O-GlcNAc Transferase (OGT)
There are multiple studies providing direct evidence for regulation of OGT activity in playing a role in diabetes. A recent report demonstrated that OGT and O-GlcNAc modified protein levels are increased in the pancreatic islets of diabetic rats (1) . Studies in OGT overexpressing transgenic mice, in which overexpression was targeted to muscle and fat tissues, demonstrated that even a moderate overexpression of OGT (~20%) was sufficient to cause insulin resistance (76) . Additionally, overexpression of OGT in liver resulted in an impairment of insulin-responsive genes and the establishment of insulin resistance (118) .
Likewise, C. elegans expressing an OGT -/-null allele exhibited dramatic changes in metabolism and impairment of dauer larva formation by the insulin-like receptor gene daf-2 (36) , providing a unique model to study OGT function in insulin signaling and resistance.
Increased GlcNAcylation also appears to be important in the pathogenesis of diabetic complications, such as diabetic cardiomyopathy. Overexpression of OGT in cardiomyocytes induced a phenotype common to diabetes-associated cardiac dysfunction, hyperGlcNAcylation and impaired calcium cycling via transcriptional inhibition of sarcoplasmic reticulum Ca 2+ ATPase (SERCA2a) (16) . This phenotype could be reversed by ectopic expression of OGA, lowering global GlcNAcylation levels. In a recent study, OGT was shown to be phosphorylated and activated by calmodulin-dependent protein kinase IV (CaMKIV) in vivo and in vitro (94) . It was further demonstrated that membrane depolarization promoted OGT activation and elevated total protein GlcNAcylation in neuroblastoma NG-108-15 cells, but interestingly, inhibition of either voltage-gated calcium channels or CaMKIV could ablate this effect (94) . Taken together these results suggest that OGT activity can be regulated by calcium flux and CaMKIV dependent phosphorylation.
OGT regulates multiple cellular processes, including transcription, translation, signaling, protein localization, and cytoskeletal reorganization (38, 69, 110) . OGT knockout embryonic stem cells are not viable, highlighting the importance of O-GlcNAc in vital cellular processes (90) . OGT has been purified, characterized and is highly conserved in a number of organisms ranging from C. elegans to humans (63, 70) . The OGT gene maps to a region on chromosome Xq13 that has been linked to Parkinson's disease (79) . Unfortunately, the full crystal structure of OGT has not been solved, which would provide vital insight into the mechanisms regulating GlcNAcylation of proteins. In addition to its regulation by UDPGlcNAc, OGT's specificity and activity toward specific protein substrates is controlled by protein-protein interactions with its ~eleven tetratricopeptide repeat (TPR) protein docking domains (7, 64, 71) . Recently, the crystal structure of the TPR domains of OGT was reported and found to be remarkably similar to the TPR domains of importin-α (52), a protein that serves as a transport protein to carry proteins across the nuclear envelope (29, 43). Thus, it is likely that OGT substrate targeting is regulated in a manner similar to the regulation of importin-α mediated nuclear transport.
In the past, functional studies focusing on inhibition of OGT enzymatic activity and/or transcriptional suppression of OGT (e.g. by siRNA) have been limited due to a lack of potent in vivo inhibitors and the protein's long half life. However, recent studies have shown that siRNA targeted knockdown of OGT can be achieved (13, 86) . Some micro molar OGT inhibitors have been developed, and new strategies are actively being pursued to develop novel, specific, and potent OGT inhibitors. One such strategy has been recently published (31) . Although alloxan, a uridine analog, which is often used to induce diabetes in animals, has been used to inhibit OGT (13, 61) , it unfortunately is a very non-specific inhibitor of many enzymes using uridine containing substrates, and is chemically reactive with many cellular components, including DNA (96).
Regulation of O-GlcNAcase (OGA)
O-GlcNAcase (OGA) was first described as hexosaminidase C in cytosolic extracts (9), later purified and characterized (20) , and subsequently cloned and sequenced (26) OGA is expressed in all tissue types examined, and has a tissue distribution similar to OGT, but unlike OGT, which is mostly in the nucleus, OGA is mostly localized in the cytoplasm (26) . However, on average approximately twenty-percent of OGT is within the cytoplasm and an equivalent proportion of OGA is found within the nucleus. The OGA gene was found to be identical to MGEA5, which was initially identified to be associated with human meningiomas (42) . The OGA gene also maps to a region on chromosome 10q24.1, which has been linked to Alzheimer's disease (6), sometimes referred to as "diabetes type 3" (17) . As with OGT, the mechanisms by which OGA is regulated in response to certain stimuli are not well understood. OGA may be regulated during apoptosis via specific cleavage by caspase-3; however, the cleavage does not seem to have an adverse effect on OGA activity in vitro (107) , and may play other roles in either the localization or targeting of the enzyme.
Currently, the crystal structure of OGA has not been solved. As with OGT, the crystal structure of OGA would provide structural insights into the mechanism by which OGA may regulate O-GlcNAc cycling and insulin resistance.
The discoveries of OGA inhibitors have greatly aided in the study and understanding of OGlcNAc, but their use can be associated with some drawbacks. PUGNAc, while successfully inhibiting OGA to increase O-GlcNAc levels, may also cause the inhibition of various lysosomal hexosaminidases therefore complicating the interpretation of results as being a
-thiazoline (NAG-thialozine (GT)) was found to be a more selective and specific inhibitor of OGA and is now preferred over PUGNAc (59, 114) . However, recent studies have also indicated that these commonly used inhibitors may have distinctly different effects on different isoforms of OGA (58) . Although reported in the literature (60, 68) , the GlcNAc analog, streptozotocin (STZ) is, in fact, a poor inhibitor of OGA (37) and has many other toxic side effects to cells.
Evidence for a Direct Role of O-GlcNAc in Insulin Resistance
While multiple studies demonstrate a strong association between insulin resistance and perturbation of O-GlcNAc pathways, a direct causal role for O-GlcNAc in the development of insulin resistance remains controversial. Elevation of O-GlcNAc levels causes insulin resistance and impaired glucose uptake in multiple cell types (76, 103) . Therefore, it has been proposed that blocking nutrient-dependent increases in GlcNAcylation might also prevent nutrient-induced insulin resistance. However, Robinson et. al. recently reported that chronic reduction of protein O-GlcNAc levels by overexpressing OGA does not prevent insulin resistance upon sustained treatment with glucose and low dose insulin (86) . In these studies, although global GlcNAcylation levels were decreased, specific effects of OGA overexpression on the GlcNAcylation of proteins within the insulin signaling pathway were not determined. Since isoforms or holo-enzyme complexes of OGA are known to have different inhibitor sensitivities and perhaps different substrate specificities, future studies will need to examine the effect of OGA expression on the GlcNAcylation of individual site(s) on these key signaling proteins. These authors also note that OGA expression and its activity was mainly cytosolic, confirming a previous report, which demonstrated that overexpression of OGA has limited nuclear expression (26) . To overcome this technical shortcoming, these investigators took another approach using siRNA-targeted knockdown of OGT to determine whether decreased or inhibited GlcNAcylation could prevent insulin resistance. Similarly, a ~90% knockdown of OGT expression and consequent global decrease in GlcNAcylation levels (to a similar degree) did not prevent the development of insulin resistance in 3T3-L1 adipocytes (86) , which appears to contradict the conclusions of early studies in this same cell type (74, 75) . Molecular interpretation of these results will also require a study of the effects of OGT RNAi on GlcNAcylation of specific site(s) on key insulin signaling proteins. Very recent data suggests that GlcNAcylation indeed does play a role in insulin resistance mediated by OGT targeting to the plasma membrane via phosphoinositides to increase
GlcNAcylation of key components within the insulin signaling pathway (118) . Thus, existing data strongly suggest that elevated O-GlcNAc, can itself induce insulin resistance, but clearly many other molecular events contribute to insulin resistance (10, 86) .
Regulation of OGT/OGA targeting and complex formation in Insulin Resistance
Unlike the presence of five-hundred and eighteen kinase genes in the human genome (73) the myriad nucleocytoplasmic proteins are specifically O-GlcNAc modified by only one single highly-conserved catalytic subunit, OGT (63) . Thus, OGT targeting and specificity is quite different than that for kinases (50 Several studies have shown that when Thr-58 of c-Myc is mutated to a non-hydroxyamino acid, this transcription factor becomes an oncoprotein (3, 32) . However, since Thr-58 is OGlcNAc modified in non-growing cells (54) , and phosphorylated by GSK-3β kinase in growing cells, the functional significance of each PTM remains unclear. Additionally, the majority of proteins whose O-GlcNAc sites have been mapped (>80%) were isolated from brain and spinal cord not from other tissues relevant to diabetes and metabolism (i.e. muscle, liver, and fat). Of all proteins O-GlcNAc site-mapped to date, only two (nuclear pore glycoprotein p62 and FoxO1; Suppl. Fig. 1 ) has been mapped in a tissue, which is metabolically directly responsive to insulin (i.e. liver). Interestingly, under these same conditions GlcNAcylation of eNOS is increased, while phosphorylation at Ser-1177 is decreased (21) , suggesting that there may be some OGlcNAc/O-phosphate interplay. These results also suggest that the O-GlcNAc site of eNOS may be Ser-1177, but this remains to be definitively proven by mass spectrometry techniques, such as those briefly described later. Furthermore, elevated GlcNAcylation of eNOS was shown to inhibit its subsequent activation by Akt (21) , suggesting that the site of GlcNAcylation is at or near the Akt phosphorylation site. GlcNAcylation of eNOS has been implicated in diabetic erectile dysfunction (80) . Glycogen synthase (GS) has been demonstrated to be O-GlcNAc modified in 3T3-L1 adipocytes (82) . GlcNAcylation of GS was demonstrated to reduce its ability to be activated by insulin (Figure 2 , muscle/fat cell) (81, 82) . Diabetic streptozotocin (STZ) treated mice had reduced GS activity and increased GlcNAcylation of GS (81, 82) . This suggests that O-GlcNAc is involved in some aspect of regulating GS function.
GlcNAcylation of Proteins Regulating Glucose-Dependent Insulin Expression OGT and O-GlcNAc
The above represents a review of a number of glucose responsive proteins identified as being O-GlcNAc modified (e.g. NeuroD1a, PDX-1, Sp1, CRTC2, FoxO1, eNOS, and GS)
with data suggestive of O-GlcNAc having a functional role on these proteins. However, these studies have also highlighted the need for more site-specific O-GlcNAc functional studies.
Hopefully such studies will help to elucidate the importance of this modification on specific residues in regulating proteins involved in mediating the many aspects of insulin resistance and the pathogenesis of type II diabetes.
Identification of O-GlcNAcylated residues on Metabolically Relevant Proteins
Of the 75 proteins that have had their O-GlcNAc site(s) mapped or localized, (Suppl. table 1), 12 proteins were chosen as having established metabolic relevance and are listed in Table 1 . One of these proteins, insulin receptor substrate 1 (IRS-1), is directly involved in mediating insulin signaling by acting as a major intracellular docking/adaptor protein linking insulin-dependent receptor auto-phosphorylation events to downstream signaling cascades resulting in GLUT4 translocation (Figure 2 , muscle/fat cell). Mass spectrometric studies along with site-directed mutagenesis have confirmed that Ser-1036 is a major site of GlcNAcylation of IRS-1 (5). A UniProtKB database search did not reveal any known phosphorylation sites located within 5 amino acids of this O-GlcNAc site (Table 1) .
Therefore, a direct O-GlcNAc/O-phosphate interplay at Ser-1036 may not be a functional possibility in the regulation of IRS-1. However, it is important to note that in the 3-D structure of a protein, two seemingly distant residues could be in close proximity. In any case, the functional significance of GlcNAcylation of Ser-1036 on IRS-1 remains to be elucidated.
Two other metabolically relevant proteins that have had their O-GlcNAc sites mapped are CRTC2 and FoxO1. As stated in the previous section, high glucose induced GlcNAcylation of CRTC2 and FoxO1 mediates hepatic gluconeogenesis. However, in contrast to IRS-1, a site-specific functional role for these modifications has been established. Under normal conditions CRTC2, a CREB transcriptional factor co-activator for CREB, is phosphorylated at both Ser-70 and Ser-171 causing it to be sequestered in the cytoplasm by 14-3-3 proteins.
However, it was recently demonstrated that under high glucose conditions CRTC2 becomes GlcNAcylated at Ser-70 and Ser-171, resulting in its nuclear translocation and transcription of hepatic gluconeogeneic genes (i.e. glucose-6-phosphate and PEPCK) (18) (Figure 3 ).
Mutations at these two residues disrupted the CRTC2:14-3-3 proteins interaction and resulted in the nuclear localization of the CRTC2 mutants (18) . This result is consistent with the increasing data that suggests a functional and dynamic interplay exists between GlcNAcylation and phosphorylation. In a separate study, it was demonstrated that hepatic FoxO1 GlcNAcylation is increased in STZ treated rats (45, 46) . FoxO1 also controls the expression of gluconeogeneic enzymes glucose-6-phosphatase and PEPCK. Under hyperglycemic conditions, FoxO1 is GlcNAcylated on Thr-317 resulting in an increase in its transcriptional activity (Figure 3) (45, 46) . Mutation of Thr-317 to an alanine decreased FoxO1 activation during a luciferase reporter assay in response to high glucose (46) . Published phospho-sites (as cited by the UniProtKB protein database) are in "BOLD red font". † Proteins from the respective species that could not be located on the UniProtKB protein database. 
